Enumeral Biomedical And Memorial Sloan-Kettering Cancer Center To Research Cancer Immunology With Advanced Prototype System For Human Tissue Immuno-Oncology Profiling

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that the company signed an agreement with Memorial Sloan Kettering (MSK) Cancer Center as part of Enumeral’s Phase II Small Business Innovation Research (SBIR) contract with the National Cancer Institute (NCI). Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed at MSK in the laboratory of Jedd D. Wolchok, M.D., Ph.D., Chief of Melanoma and Immunotherapeutics Service, Lloyd J. Old/Ludwig Chair in Clinical Investigation Department of Medicine and Ludwig Center, at Memorial Sloan Kettering Cancer Center. Dr. Wolchok played a critical role in the clinical development of ipilimumab and nivolumab, immunotherapies which represent a transformational advancement in the treatment of cancer.

“Examining the human tumor microenvironment and identifying signatures from rare immune cells may significantly impact our understanding of human response to immunotherapeutics.”

“We are excited to have access to Enumeral’s technology and apply it to our efforts in cancer immunology,” said Dr. Wolchok. “Examining the human tumor microenvironment and identifying signatures from rare immune cells may significantly impact our understanding of human response to immunotherapeutics.”

Enumeral’s Phase II program is focused on applying its human-driven immune profiling platform to “small volume” clinical specimens such as core biopsy or fine needle aspirates, which often contain limited numbers of cells and can be challenging to analyze with conventional technologies. Enumeral’s human-driven immune profiling platform has the ability to determine cellular function in an unbiased fashion, allowing analysis of rare immune cells associated with disease or drug response in even the smallest clinical samples. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response, which may ultimately guide development of more precisely targeted immunotherapies.

“Dr. Wolchok is a world recognized leader in the research and clinical development of cancer immunotherapies, and we are thrilled to work with his team to advance the potential clinical impact of our profiling technology,” said Arthur H. Tinkelenberg, Ph.D., President and CEO of Enumeral.

Enumeral’s collaboration with MSK is supported by a Phase II SBIR contract from the NCI for $999,967 over two years. The NCI is funding the entirety of the program, which complements Enumeral’s other internal research and development efforts. Enumeral demonstrated proof of concept in this area under a Phase I contract in 2012 and 2013.

About Enumeral’s Human-driven Immune Profiling Platform

Enumeral’s human-driven immune profiling platform is enabling and accelerating the discovery and development of novel antibody immunotherapies, or immunomodulators. The core technology behind Enumeral’s platform was developed at and licensed from the Massachusetts Institute of Technology, Harvard University, Whitehead Institute for Biomedical Research and Massachusetts General Hospital.

Enumeral performs measurements on single immune cells in order to mine the immune system’s rich collection of cells for information that is difficult to obtain using other methods and that may guide the development of effective therapeutics and diagnostics. The efficiency and sensitivity provided through our platform increases the probability of finding rare immune cells associated with disease or drug response. Studying rare immune cells obtained directly from human patients for their functional responses can potentially lead to selection of best-in-class antibody drug candidates that may have a higher likelihood of successful development. Such knowledge generated from our platform is being applied to better understand which drug candidates might work in which patients, and, at what stage of disease.

About Enumeral

Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. We believe we have a unique ability to extensively interrogate the human immune microenvironment for candidate selection and validation. We believe our unique capabilities enable us to measure drug effects in a patient-specific manner, providing the basis for developing best-in-class product candidates, based on a fundamental understanding of how immunotherapies work in each patient. We are building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and leveraging the breadth of our technology through strategic collaborations. www.enumeral.com

Forward Looking Statements Disclosure

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements reflect current beliefs of Enumeral Biomedical Holdings, Inc. (“Enumeral”) with respect to future events and involve known and unknown risks, uncertainties, and other factors affecting operations, market growth, services, products and licenses. No assurances can be given regarding the achievement of future results, and although Enumeral believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, actual results may differ from the assumptions underlying the statements that have been made regarding anticipated events. More detailed information about Enumeral and risk factors that may affect the realization of forward-looking statements, including forward-looking statements in this press release, is set forth in Enumeral’s filings with the Securities and Exchange Commission. Enumeral urges investors and security holders to read those documents free of charge at the Commission’s website at http://www.sec.gov. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, Enumeral undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

Help employers find you! Check out all the jobs and post your resume.